Risk of Thromboembolism in Nonvalvular Atrial Fibrillation

Main Article Content

AlHarbi, Hassan M.
Abdulazizi I. Alroshodi
Ghazi T. AlMutairi
Abdullah A. Alfhaid
Mashari Alzahrani
Khaled A. Alqarni
Naif Saad Alghasab
Alzead, Ahmed A.
Mashary A. Attamimi
Fahad Alshehri


Background: Atrial fibrillation is associated with atrial thrombus formation and peripheral embolization, which leads to ischemic stroke or systemic thromboembolism. The CHADS2, CHA2DS2-VASc scores are tool for estimating risk of stroke in nonvalvular atrial fibrillation (NVAF) patients. Data on scores variables, Body mass index (BMI) and chronic kidney disease (CKD) with reduced glomerular filtration rate on their implication in identify thromboembolic events (TE) in Saudi population with NVAF are quite limited.

Methods: The study consisted of 541 patients with AF seen in our institution from 2008 to 2013 were identified in database, 175 were NVAF. Thromboembolic end points were defined as ischemic stroke and systemic embolism. During follow - up period of 730 days. CHADS2, CHA2DS2-VASc scores components, BMI also CKD and association with TEs end points identified by Cox regression analysis.

Results: Of 175 patients with NVAF, 26 (14.9%) patients were identified to have TEs. Majority of them had stroke. Age (>or =75 years) and Peripheral vascular disease were significant factors for TEs. Thromboembolic risk in patients had previous stroke or TIA was 38.5% (P value =.000). Events rate of thromboembolism increased when CHADS2/ CHA2DS2-VASc score increased. No statistically significant associations were observed with BMI and TEs. Study has shown Despite only 35% of study population is suffering from CKD however level of estimated glomerular filtration rate were significant factor for TEs in patients with nonvalvular atrial fibrillation.

Conclusion: Study demonstrated CHADS2, CHA2DS2-VASc, CKD are predictor of TEs and should be included in risk stratification schemes among NVAF Saudi patient. While obesity was not predicator for TEs. So, keeping this association in consideration during thromboembolism risk assessment is recommended. Further study is needed to search for modifiable risk factors that are associated with increased risk thromboembolism in NVAF patient In addition to the conventional CHADS2/ CHA2DS2-VASc scheme.

Atrial fibrillation, risk of thromboembolism, body mass index and chronic kidney.

Article Details

How to Cite
Hassan M., A., Alroshodi, A. I., AlMutairi, G. T., Alfhaid, A. A., Alzahrani, M., Alqarni, K. A., Alghasab, N. S., Ahmed A., A., Attamimi, M. A., & Alshehri, F. (2020). Risk of Thromboembolism in Nonvalvular Atrial Fibrillation. Asian Journal of Cardiology Research, 3(1), 16-24. Retrieved from https://journalajcr.com/index.php/AJCR/article/view/30102
Original Research Article


Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: Final results. Circulation. 1991;84:527–539.

Risk of Stroke with AF. VA Palo Alto Medical Center and at Stanford University: The Sportsmedicine Program and the Cardiomyopathy Clinic; 2007.

(Retrieved 2007-09-14)

Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70.

Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA. 2003;290:2685.

Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate onriskofthromboembolism in atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2009;119:1363–1369.

Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–635.

Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation.

Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J Am Heart Assoc. 2013;2:e000250.

DOI: 10.1161/JAHA.113.000250

Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Circulation. 2011;123(14):1501-8.

Tang RB, Liu XH, Kalifa J, Li ZA, Dong JZ, Yang Y, Liu XP, Long DY, Yu RH, Ma CS. Am J Cardiol. 2009;104(12):1699- 703.

Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927–934.

Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.

Coppens M, Eikelboom JW, Hart RG, et al. The CHA2DS2 VASc identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J. 2013;34:170–176.

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke. 1991;22:983–8.

Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) investigators. Stroke. 1999;30:1223–9.

Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005;112:1687–91.

Tomita H, Okumura K, Inoue H, Atarashi H, Yamashita T, Origasa H, Tsushima E, J-RHYTHM Registry Investigators. Validation of risk scoring system excluding female sex from CHA2DS2-VASc in Japanese patients with nonvalvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry. Circ J. 2015;79:1719–1726.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. K2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.

Overvad TF, Nielsen PB, Lip GYTreatment thresholds for stroke prevention in atrial fibrillation: Observations on the CHA2DS2-VASc score. Eur Heart J Cardiovasc Pharmacother. 2017;3:37–41.

January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071–2104.

Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology and rationale for therapy. American Journal of Cardiology. 2003;91(1):2-8.

McFarlane SI, Sica DA, Sowers JRJ. Stroke in patients with diabetes and hypertension. Clin Hypertens (Greenwich). 2005;7(5):286-92; quiz 293-4.

Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GYHJensen M. Glycemic status and thromboembolic risk in patients with atrial fibrillation and type 2 diabetes: A Danish cohort study. Circ Arrhythmia Electrophysiol. 2019;12: e007030.

Ashburner JM, Go AS, Chang Y, Fang MC, Fredman L, Applebaum KM, Singer DE. Effect of diabetes and glycemic control on ischemic stroke risk in AF patients: Atria study. J Am Coll Cardiol. 2016;67:239–247.

DOI: 10.1016/j.jacc.2015.10.080

Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study. J Stroke Cerebrovasc Dis. 1995;5:147– 57.

Stöllberger C, Chnupa P, Abzieher C, Länger T, Finsterer J, Klem I, et al. Clin Cardiol. 2004;27(1):40-6.

Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC, Seward JB, Gersh. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: A longitudinal cohort study of 21 years. BJ Eur Heart J. 2008;29(18):2227-33.

Zhu W, Wan R, Liu F, et al. Relation of body mass index with adverse outcomes among patients with atrial fibrillation: A meta-analysis and systematic review. J Am Heart Assoc. 2016;5:e004006.

Zamora E, Díez-López C, Lupón J, de Antonio M, Domingo M, Santesmases J, et al. Weight loss in obese patients with heart failure. J Am Heart Assoc. 2016;5(3): e002468–e002468.

Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: Implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011;57:1339–1348.

Roldán V, Marín F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost. 2013;109(5):956-960.

Kornej J, Hindricks G, Kosiuk J, et al. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc and R2CHADS2.

Jelena Kornej, Gerhard Hindricks, Jedrzej Kosiuk, Arash Arya, Philipp Sommer, Daniela Husser, et al. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2) and the risk of thromboembolic events after catheter ablation of atrial fibrillation. Circ. Arrhythmia and Electrophysiology. 2013;6:868–874.